



(51) International Patent Classification:

A61P 9/10 (2006.01) A61K 38/13 (2006.01)
A61K 35/545 (2015.01) A61K 35/34 (2015.01)

(21) International Application Number:

PCT/US2022/017268

(22) International Filing Date:

22 February 2022 (22.02.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/152,737 23 February 2021 (23.02.2021) US

(71) Applicant: **UNIVERSITY OF WASHINGTON**
[US/US]; 4545 Roosevelt Way NE, Suite 400, Seattle,
Washington 98105 (US).

(72) Inventors: **MURRY, Charles E.**; c/o University of Wash-
ington, 4545 Roosevelt Way NE, Suite 400, Seattle, Wash-
ington 98105 (US). **MACLELLAN, William Robb**; c/o
University of Washington, 4545 Roosevelt Way NE, Suite
400, Seattle, Washington 98105 (US). **THIES, Robert
Scott**; c/o University of Washington, 4545 Roosevelt Way
NE, Suite 400, Seattle, Washington 98105 (US). **NAKA-**

MURA, Kenta; c/o University of Washington, 4545 Roo-
sevelt Way NE, Suite 400, Seattle, Washington 98105 (US).
NAKAMURA, Daisy Sue; c/o University of Washington,
4545 Roosevelt Way NE, Suite 400, Seattle, Washington
98105 (US). **NEIDIG, Lauren E.**; c/o University of Wash-
ington, 4545 Roosevelt Way NE, Suite 400, Seattle, Wash-
ington 98105 (US).

(74) Agent: **FITZGERALD, Mark J.** et al.; Nixon Peabody
LLP, Exchange Place, 53 State Street, Boston, Massachu-
setts 02109 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(54) Title: COMPOSITIONS AND METHODS FOR CARDIOMYOCYTE TRANSPLANTATION




FIG. 1

(57) Abstract: The present disclosure provides for the treatment of cardiac diseases and disorders using in vitro-differentiated cardiomyocytes. Such methods can take advantage of both autologous and allogeneic pluripotent stem cells.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*